Omeros Q3: YARTEMLEA Sales $35.9M, Net Loss $57.4M on Non-Cash Derivative Mark
OMER has more than doubled off its 52-week low of $6.59.
Summary
Omeros' Q3 loss of $57.4 million was driven by a $62.0 million non-cash derivative remeasurement, while YARTEMLEA sales grew 26% sequentially to $35.9 million and the company generated $13.3 million of quarterly operating cash flow.
Key Events · Earnings and Guidance · OMER
-
YARTEMLEA Sales Grow 26% Sequentially
Q3 net product sales were $35.9 million versus $28.5 million in Q2 (a $7.4 million, 26.0% increase), with 109 unique ordering accounts by September 30, up 49% since June 30.
-
Loss Driven by Non-Cash Derivative Mark
The $57.4 million net loss includes a $62.0 million non-cash loss on remeasurement of the 2029 Notes embedded derivative and repurchase obligation as the stock price rose — no cash outflow and no change in share count.
-
Operating Cash Flow Turns Positive
Cash provided by operations was $13.3 million for Q3 and $2.9 million for the nine months, versus $76.3 million used in the prior-year nine-month period; cash and short-term investments totaled $95.3 million at September 30.
-
EU Approval Path Effectively Closed
CHMP upheld its negative opinion on narsoplimab for TA-TMA on October 16, 2026 after re-examination, so Omeros does not expect EU marketing authorization on the current MAA.
Analysis · OMER · Life Sciences
The headline $57.4 million quarterly loss is almost entirely a non-cash accounting swing: a $62.0 million mark-to-market loss on the 2029 Notes conversion derivative as the stock rose, not a cash outflow and not new dilution. The operating story is better than the bottom line suggests — YARTEMLEA net sales reached $35.9 million, up 26.0% from Q2, with 109 ordering accounts (a 49% increase since June 30), and the company generated $13.3 million of cash from operations in the quarter. Cash and investments of $95.3 million plus commercial sales are expected to fund more than 12 months of operations. The offsetting negatives: the EU path for narsoplimab is effectively closed after CHMP upheld its negative opinion on October 16, and SG&A is climbing as the commercial build-out continues.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OMER was trading at $15.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $6.59 to $21.24. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.